虚血性脳卒中のマウス モデルで [¹¹C] DPA-713 Neuroinflammation のイメージングをペットします。

Executive Industry Relevance

Neuroinflammation is a key driver of pathological progression in ischemic stroke and other neurodegenerative diseases, yet its dynamic spatiotemporal evolution remains challenging to capture with static post-mortem methods. Non-invasive PET imaging using TSPO-targeted radiotracers like [¹¹C]DPA-713 enables real-time, longitudinal quantification of microglial activation in living systems, providing critical mechanistic insights for target validation and therapeutic de-risking in neuroinflammatory pathways. This approach supports early discovery by delivering quantitative, translatable biomarkers that inform go/no-go decisions in preclinical pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of TSPO as a biomarker for microglial activation, supporting target hypothesis testing in neuroinflammatory pathways.
• Operational Value: Provides quantitative, longitudinal readouts of target engagement and biological response in vivo.
• Predictive Value: Facilitates mechanistic de-risking by linking TSPO expression to disease-relevant neuroinflammatory cascades in stroke models.

Screening & Assay Development

• Scientific Value: Generates standardized, reproducible PET-derived uptake metrics (e.g., ipsilateral vs. contralateral hemispheres) for comparative compound or genotype screening.
• Operational Value: Supports high-throughput experimental design through simultaneous multi-animal imaging, improving resource efficiency and data consistency.
• Assay Readiness: Establishes validated quantification protocols using manual ROI analysis and time-activity curves for downstream translational applications.

Translational & Preclinical Research

• Scientific Value: Enables correlation of in vivo PET signals with ex vivo autoradiography, strengthening target validation and biomarker reliability.
• Operational Value: Bridges discovery and preclinical workflows by providing non-invasive, repeatable monitoring of neuroinflammatory burden across disease progression.
• Translational Continuity: Supports biomarker qualification efforts by delivering quantifiable, disease-relevant neuroinflammatory readouts applicable to stroke and related CNS indications.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from target validation through lead optimization, offering a non-invasive imaging modality to monitor neuroinflammatory responses in disease-relevant preclinical models prior to compound advancement.

• Discovery Biology: Supports hypothesis-driven interrogation of TSPO-mediated neuroinflammation, enabling pathway clarification and target de-risking in stroke and neurodegenerative disease models.
• Screening: Delivers quantitative imaging endpoints (e.g., standardized uptake values) that allow side-by-side comparison of experimental conditions, genotypes, or therapeutic interventions.
• Analytics: Generates time-activity curves and ROI-based quantification outputs that enable statistical comparison of tracer uptake between ipsilateral and contralateral brain regions.
• Translational Research: Connects in vivo imaging findings to ex vivo validation, reinforcing biomarker reliability for neuroinflammatory pathways in stroke models.
• Enterprise Reuse: Establishes a reusable imaging platform applicable across multiple neuroinflammatory disease models, maximizing return on radiotracer and instrumentation investment.

Operational & Enterprise Impact

• Scientific Value: Provides predictive confidence in TSPO as a neuroinflammatory biomarker through longitudinal, quantifiable in vivo monitoring.
• Operational Value: Enhances throughput via simultaneous multi-subject imaging, reducing per-experiment cost and accelerating data acquisition.
• Strategic Value: Improves go/no-go decision-making by delivering objective, translatable neuroinflammatory readouts that reduce biological uncertainty in target validation.
• Portfolio Impact: Enables risk-adjusted prioritization of compounds based on their ability to modulate TSPO-associated neuroinflammatory pathways in disease-relevant systems.

Implementation Considerations

• Requires expertise in PET/CT imaging, radiotracer handling, and small-animal anesthesia and cannulation techniques.
• Dependent on access to a PET/CT scanner, dose calibrator, and short-lived [¹¹C]DPA-713 radiotracer with appropriate radiochemistry infrastructure.
• Necessitates standardized operating procedures for multi-animal setup, simultaneous injection, and post-scan radioactivity measurement to ensure reproducibility and radiation safety.
• Involves image analysis expertise for co-registration, ROI drawing, and quantification using arterial or reference tissue input methods.
• Limited by the short half-life of Carbon-11 (~20 minutes), requiring precise timing and on-site radiotracer synthesis or rapid delivery to maximize usable signal and minimize decay loss.

Biopharma FAQs